Wickham Laboratories now offering stability storage & testing
23 September 2016 | By Wickham Laboratories Limited
Wickham Laboratories is pleased to introduce stability storage and testing as its latest service offering...
List view / Grid view
News
Joint article on hydrogen peroxide efficacy published in Letters in Applied Microbiology
23 September 2016 | By Wickham Laboratories Limited
Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection by hydrogen peroxide...
BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays
23 September 2016 | By BBI Solutions
BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September...
RB implements Ci-DMS Weigh and Dispense from CI Precision
23 September 2016 | By CI Precision
Global consumer goods group RB (formerly known as Reckitt Benckiser) is implementing CI Precision’s MES solution (Ci-DMS) in the dispensing area at their manufacturing plant in Pakistan...
Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent...
Coulter Partners consolidates global team with appointments in New Jersey, Newton and London
21 September 2016 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce a number of new appointments in the US and in London...
Xenikos’ T-Guard trial doses final patient with acute graft-versus-host disease
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
T-Guard has been shown to be well tolerated, with a manageable side effect profile and no severe infusion reactions in patients with acute GVHD...
First female CEO to lead GSK as Emma Walmsley succeeds Andrew Witty
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
She will succeed Andrew Witty as GSK CEO, when he retires on 31st March 2017. She will be the first female CEO of a major global pharmaceuticals company...
The new DualFUSION Vial is first vial that combines the benefits of a strong, protective plastic outer layer and the high-performance barrier properties of an inner silica layer
20 September 2016 | By WHEATON®
New line of purpose-built, ready-to-sterilize, uniquely barcoded vials will be introduced at the American Association of Clinical Chemistry Annual Meeting...
Prexton successfully completes phase 1 Parkinson’s disease trial
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally...
Edinburgh Instruments’ Spectrometers help developing infrared lasers
20 September 2016 | By Edinburgh Instruments
Research in optical materials is rapidly moving towards stable, high-power laser sources emitting in the mid-infrared (mid-IR) region...
Smartfish’s medical drink trial a success for COPD patients suffering from cachexia
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Cachexia is a condition of involuntary weight loss, undernourishment and a number of negative side-effects that can be seen in patients with Chronic obstructive pulmonary disease (COPD), as well as in cancer and in several severe inflammatory diseases, such as AIDS, congestive heart failure, tuberculosis and rheumatoid arthritis...
FDA extends PDUFA date for telotristat etiprate for the treatment of carcinoid syndrome
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In a notice from the FDA, the Prescription Drug User Fee Act date for its Priority Review of telotristat etiprate has been extended by three months...
NICE does not recommend obinutuzumab to treat follicular lymphoma
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment...
FDA approves Shire’s CUVITRU for the treatment of primary immunodeficiency
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly...
